In brief
Moderna CEO Stéphane Bancel argues that mRNA has produced the first working cancer vaccine, after more than a thousand failed trials by others. Moderna and Merck's individualized treatment, intismeran, beat Keytruda alone in a Phase 3 melanoma trial. Bancel credits two things: mRNA's way of showing the immune system a target from the inside, and a design built from each patient's own tumor.
The central tension is between biology and logistics. About 90% of the targets differ from patient to patient, so every dose must be custom-made, yet it has to be quick, safe and cheap enough to scale. Bancel says Moderna has cut the process to about 42 days and is shrinking its machines. He sees this first version as the weakest the treatment will ever be.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
Stéphane Bancel said the cancer vaccine field had run more than a thousand clinical trials over 20-plus years that had all failed.
“The field, as you know, has been doing that for 20 plus years. I think more than a thousand clinical trials that have all failed.”
0:04:31 · Stéphane Bancel · Cancer vaccines
Bancel said the Moderna and Merck Phase 3 melanoma trial also met its secondary endpoint of distant metastasis-free survival at the first interim analysis.
“we met the secondary endpoint which was distant metastasis-free survival which is of course takes more time to mature”
0:05:01 · Stéphane Bancel · Phase 3 trial · 2026
Bancel said Moderna's randomized Phase 2 melanoma study, presented at ASCO in spring 2026, showed around 50% recurrence-free survival compared with Keytruda alone, five years after treatment.
“our phase two study, which was also randomized against Ketudra alone, so the same type of study, showed that around 50 % of people had recurrence-free survival versus people only getting Ketudra.”
0:05:42 · Stéphane Bancel · Phase 2 results · 2026
Bancel said Moderna and Merck hope to have the melanoma treatment available to patients in 2027 and that the factory in Massachusetts is ready.
“we hope in 2027 and then we're going to try to make it as fast as we can The factory is ready in Massachusetts”
0:06:24 · Stéphane Bancel · Regulatory timeline · 2027
Bancel said published Phase 3 data show only about 60% of patients are disease-free five years after Keytruda treatment.
“only 60 % of people are disease-free after five years. If you look at the phase three published data of Ketudra.”
0:07:32 · Stéphane Bancel · Keytruda efficacy
Bancel said that patients treated with checkpoint inhibitors such as Keytruda commonly develop autoimmune conditions including type 1 diabetes, lupus and Crohn's disease.
“people that get checkpoints, whether it's Ketudra or any other type of checkpoints from other companies, they end up having type 1 diabetes, lupus, Crohn disease, these type of things.”
0:07:57 · Stéphane Bancel · Side effects
According to Bancel, the individualized cancer treatment technology emerged from Moderna's labs around 2015-2016, when Moderna partnered with Merck.
“a technology that emerged from Moderna Labs back in 2015, 2016 when we did a partnership with Merck as we were looking for one of the best companies in immunotherapy to partner”
0:08:25 · Stéphane Bancel · Merck partnership · 2015
Bancel said that mRNA injected into muscle travels to the lymph nodes and enters antigen-presenting cells, which are key immune cells.
“the mRNA goes down to your lymph node and enters the APCs, the antigen presenting cell, which, as you know, are key components of your immune cells.”
0:12:42 · Stéphane Bancel · Mechanism
Bancel said Moderna compares the DNA of a patient's tumor with that of a healthy cell and uses an algorithm to pick relevant mutations among hundreds or thousands.
“we're going to literally compare letter by letter, nucleotide by nucleotide. And then we're going to use an algorithm to identify all of your hundreds or thousands of mutations”
0:14:08 · Stéphane Bancel · Tumor sequencing
Bancel said Moderna selects 34 mutations and encodes them in a single mRNA molecule made in roughly 30 days for each patient.
“We select the 34 that we believe are the most relevant and we stitch them together into one big mRNA molecule, which we make in 30-ish days for you”
0:14:35 · Stéphane Bancel · Neoantigens
Bancel said that about 90% of the targeted antigens differ from one patient to another, which Moderna had not known when it started.
“around 90, 90 % of the antigen are different patient to patient. Because when we started, we had no idea because, again, the field came from shared antigen.”
0:15:02 · Stéphane Bancel · Personalization
Bancel said Moderna's mutation-selection algorithm has stayed the same from Phase 1 through Phase 3 and is about ten years old.
“the algorithm from a phase three was the same from a phase two, was the same from a phase one. But because we've been doing this for 10 years, it's a 10-year-old algorithm.”
0:16:34 · Stéphane Bancel · Algorithm
Bancel said the current version of intismeran is the worst version that will ever exist, and that Moderna plans to improve the algorithm using Phase 3 data.
“the worst version of Intismeran you're going to see for the rest of medical history”
0:18:03 · Stéphane Bancel · Algorithm updates
Bancel said the time from taking a tumor biopsy to delivering the personalized vaccine is now about 42 days.
“So the time is around 42 days now, needle to needle. So from taking the biopsy to getting the vaccine in the hospital ready for you.”
0:20:57 · Stéphane Bancel · Manufacturing time
Bancel said Moderna makes the DNA template synthetically and enzymatically, then makes the RNA from it and wraps it in lipid, without growing cells in large reactors.
“We make it all synthetic. So it's all enzymatic in liquid, in water. Then we make the RNA from the template. Then we put the lipid around it.”
0:21:38 · Stéphane Bancel · Manufacturing process
Bancel said Moderna has already made thousands of doses for nine ongoing clinical studies and that its Marlborough, Massachusetts facility can make tens of thousands.
“So we've already got thousands of doses because of nine clinical studies that are ongoing. The facility will be able to make the one in Marlboro, Mass, tens of thousands of doses.”
0:25:11 · Stéphane Bancel · Scale
Bancel said he expects the treatment to be approved as a process-based biologics license application, as CAR-T therapies were, rather than as a fixed product.
“CAR-T was also approved in the same way as we believe this one will be, which is as a process BLA, not a product BLA.”
0:28:11 · Stéphane Bancel · Regulation
Bancel said Moderna has five approved products, but its individualized cancer treatment has been handled with a process IND since it entered the clinic.
“Moderna has five product approved. So that's really product approval. On this one, the whole process since we started in the clinic, the IND was a process IND.”
0:28:11 · Stéphane Bancel · Regulation
Bancel said blood samples shown at ASCO indicated the treatment created new T cells recognizing the encoded targets that were absent before treatment.
“we have de novo, some new T-cells being created that recognize what we code in the mRNA that was not in the patient's body before the treatment.”
0:30:27 · Stéphane Bancel · T cells · 2026
Bancel said Moderna is running a Phase 3 trial in lung cancer and Phase 2 trials in kidney and bladder cancer, combining the treatment with Keytruda.
“we are in phase three for lung. We're in phase two for kidney cancer, bladder cancer.”
0:31:36 · Stéphane Bancel · Pipeline · 2026
Bancel said Moderna announced in spring 2026 a Phase 3 study of intismeran as monotherapy in stage one lung cancer.
“we announced in the spring of 2026, starting a phase three study for patients with stage one lung cancer.”
0:32:08 · Stéphane Bancel · Lung cancer · 2026
Bancel said Revolution Medicines had a new pancreatic cancer medicine targeting the KRAS mutation approved the day before the interview, and Moderna sees potential for combining it with intismeran.
“literally yesterday, you know, Revolution Medicine had a wonderful new medicine approved for pancreas cancer using the CARAS mutation.”
0:34:31 · Stéphane Bancel · Pancreatic cancer · 2026
Moderna CEO Stéphane Bancel previously appeared on the a16z podcast in December 2020 to discuss Moderna's mRNA COVID-19 vaccine.
“Stéphane joined us on the a16z podcast back in December of 2020 when we were talking about all of the work Moderna did to bring us the mRNA COVID vaccine.”
0:02:20 · Jorge Conde · Prior episode · 2020